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Abstract  
Introduction: The relationship between prolactin (PRL) and breast cancer in humans has been a 
controversial issue for a long time. Although some animal and human in vitro studies illustrated an 
undeniable effect of PRL in inducing and promoting mammary cancer, epidemiological studies have 
been less conclusive. There have been few reported cases of breast cancer in patients with 
hyperprolactinemia due to prolactinoma. 
Case Presentation: We present a case of bilateral, multifocal, metastatic, triple negative breast 
cancer in a 33-year-old female with long-standing, antipsychotic-induced hyperprolactinemia. 
Conclusion: There is a growing body of evidence on the carcinogenic effect of prolactin on 
mammary tissue. Studying tumor biology in patients with long standing hyperprolactinemia might 
prove useful in delineating the relationship between PRL and breast cancer in humans.  
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Introduction 
Unlike estrogen, the role of PRL in the 
development of breast cancer in humans has not 
been well defined. Nevertheless, there is 
accumulating evidence on the carcinogenic 
effects of hyperprolactinemia on mammary 
tissue from animal and human in vitro studies, 
and to a lesser extent from some 
epidemiological studies. Daniels et al. first 
reported a case of breast cancer in a patient 
with prolactinoma in 1976 [1]. Since then, 
eleven more cases were reported in both male 
and female patients who had breast cancer and 
prolactinoma [2-11]. Hyperprolactinemia was 
postulated to play a role in the development of 
breast cancer in these cases. We present a case 
of bilateral, multifocal, metastatic, triple 
negative breast cancer in a young female with 
long-standing, antipsychotic-induced 
hyperprolactinemia. 
Case report 
A 33-year-old female presented complaining of 
masses in both of her breasts. She took notice 
of the masses 3 months earlier owing to pain 
felt in both breasts, and reported a perceptible 
increase in the size of the masses since first 
noted. The patient had her menarche at the age 
of fifteen. She had three full term pregnancies, 
first of which was at the age of twenty-five, and 
she did not breast-feed any of her offspring. 
When queried, the patient stated that she did 
not use any form of contraception in her life. 
She denied any family history of breast or 
ovarian cancer, and she did not have any 
previous breast biopsies. Her past medical 
history was significant for a diagnosis of 
schizophrenia, for which she was being treated 
with the atypical antipsychotic Paliperidone 
(6mg p.o. once daily) for the past thirteen years. 
Treatment with Paliperidone was accompanied 
by hyperprolactinemia, galactorrhea, and 
amenorrhea for the past twelve years, and PRL 
levels were persistently high (2,069 mIU/L at 
time of presentation) despite treatment with 
bromocriptine (5mg p.o. once daily). A 
previous MRI of the sella turcica was normal. 
On physical exam, the Lt. nipple appeared 
retracted. There were multiple contiguous 
irregular masses involving most of the breast 
including the retroareolar region bilaterally. In 
addition, there were few palpable axillary 
lymph nodes bilaterally.  
 
Bilateral mammogram revealed highly 
suspicious masses and scattered 
microcalcification on both sides. The breast 
parenchyma was remarkably dense, 
significantly reducing the yield of the exam. 
Breast ultrasound showed multiple hypoechoic 
masses with irregular outlines replacing most of 
the breast parenchyma (Fig.1). Contrast 
enhanced breast MRI showed bilateral irregular 
breast masses that displayed rapid contrast 
uptake followed by washout (Kuhl curve type 
III). The largest mass on the Rt. side measured 
7.5cm, and the largest on the Lt. side measured 
5.1cm. Masses occupied most of the breasts 
parenchyma, and some of the masses showed 
internal necrosis (Fig.2). In addition, multiple 
enlarged axillary lymph nodes were present. 
Large-core needle biopsies were obtained from 
both breasts and showed 
Scarff-Bloom-Richardson (SBR) grade II 
invasive ductal carcinoma (tubular score:3, 
nuclear score:3, mitotic score:1). A staging CT 
scan showed multiple enlarged supraclavicular 
lymph nodes bilaterally, in addition to enlarged 
mediastinal lymph nodes, some of which 
exhibited necrosis. A solitary nodule was noted 
in the lingula of the Lt. lung. Technicium99m 
MDP whole body bone scan did not detect any 
metastatic bone lesions. An 18F-FDG PET/CT 
scan of the whole body confirmed the 
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metastatic nature of the supraclavicular and 
mediastinal lymph nodes, along with the Lt. 
lung lesion, with the addition of a new 
metastatic lesion in the middle lobe of the Rt. 
lung that was not seen on the initial staging CT 
(Fig.3).  
 
 
Figure 1 Ultrasound image of the Rt. breast 
demonstrating multiple hypoechoic contiguous 
masses with irregular outlines occupying most of 
the Rt. breast. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Breast MRI with contrast showing 
multiple bilateral enhancing irregular masses, 
almost replacing the whole of the breast 
parenchyma. 
 
The patient received three cycles of 
chemotherapy. Response to treatment has been 
unsatisfactory so far, with less than 20% 
decrease in the volume of the primary tumor, 
and the appearance of new sub-pleural 
metastatic lesions in the lung. 
Discussion 
The relationship between antipsychotics use 
and hyperprolactinemia is well established. The 
use of any antipsychotic is potentially 
associated with a transient elevation in serum 
levels of PRL [12]. Antipsychotics that 
dissociate slowly from the D2 receptors result 
in protracted blockade of the receptors, and 
consequently result in greater PRL release [13]. 
Conversely, antipsychotics that have higher 
ability to cross the blood-brain barrier are more 
likely to occupy central (striatal) D2 receptors, 
leaving more pituitary D2 receptors unoccupied, 
and resulting in less PRL release [14]. 
 
 
Figure 3 Whole body 18F-FDG PET scan showing 
the primary breast tumors (Br), the involved axillary 
lymph nodes (Ax), the metastatic mediastinal lymph 
nodes (Med), and the metastatic lung lesions (L). 
 
The effects of hyperprolactinemia on 
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mammary cancer in rodent models, and in 
human in vitro models, have been well 
documented. PRL has been shown to increase 
the growth of tumor cells, boost the 
development of chemically induced mammary 
cancer, and even induce mammary cancer in 
rodent models [15]. In vitro studies of human 
mammary tissue have shown that prolactin 
receptors (PRLRs) are expressed at higher 
levels in breast cancer cells than in normal 
mammary tissue [16], and that breast cancer 
cells locally produce PRL that may act as a 
major local growth promoter via autocrine and 
paracrine loop mechanism [17]. PRL has been 
found to increase growth, inhibit apoptosis, 
enhance motility, and increase vascularization 
of human breast cancer cells cultures [15]. 
Antibodies that neutralize locally expressed 
(autocrine) PRL have been shown to result in 
inhibition of cell growth in such tumors [18].  
 
From an epidemiological point of view, the 
largest prospective case controlled study to date 
of 1,500 women conducted by Tworoger et al., 
has shown a 30% higher breast cancer risk, 
which increased to 70% after measurement 
error correction, for the women with the highest 
versus the women with the lowest PRL 
concentrations in the study [19]. This effect 
was observed in both cycling premenopausal 
and postmenopausal women, and was 
independent of estradiol and testosterone 
concentrations. Wang et al. have demonstrated 
in a retrospective cohort study conducted on 
52819 women who were exposed, and 55289 
who were not exposed to dopamine antagonists, 
that the use of antipsychotic dopamine 
antagonists was associated with a 16% increase 
in the risk of breast cancer, and that the risk 
increased with larger cumulative dosages [20]. 
This increased risk was likewise observed in 
women who used prolactin-elevating antiemetic 
dopamine antagonists, but at the same time it 
was not observed for other types of cancer like 
colon cancer, pointing to the fact that the 
increase in risk was primarily attributable to the 
drug-induced elevation of PRL and its effects 
on mammary tissue, and not to any other 
carcinogenic effect of the dopamine 
antagonists. 
 
It is surprising therefore, with this growing 
body of evidence on the role of PRL in 
increasing the risk for breast cancer, to find that 
there have been only few published reports 
describing breast cancer in patients with greatly 
elevated PRL levels, mostly in men and women 
having breast cancer with prolactinomas. Of the 
thirteen reported cases (including ours), the 
diagnosis of hyperprolactinemia preceded the 
diagnosis of breast cancer in eleven cases 
[1-5,7,8,10,11], with a mean interval of 16 
years (range 3-36 years). Both conditions were 
concomitantly diagnosed in two of the cases [6, 
9]. Five of the cases (5/13) were males 
[3,6,8,9,11], six (6/13) were patients younger 
than 35 years of age [1,2,4,5,7] (mean age 44 
years), and four (4/13) had tumors bilaterally 
[3,8,9]. The hormone receptor status of the 
tumor was not documented in the earliest four 
reports [1-4], however, in the remaining nine 
cases, all aside from our case (8/9) expressed 
estrogen receptors [5-11], and in four cases 
(4/9), both estrogen and progesterone receptors 
were expressed [5,8-10].  
 
Our case is unique in the fact that 
hyperprolactinemia was drug induced and not 
due to a prolactinoma. In addition, all of the 
previously reported cases with documented 
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hormone receptor status were positive for 
estrogen receptors, while our patient had a 
triple negative hormone receptor status. In the 
epidemiological study by Tworoger et al 
mentioned earlier, the observed positive 
association between high PRL levels and breast 
cancer was exclusive to estrogen receptor 
positive tumors [19]. On the other hand, 
Pattison et al. reported on a case of breast 
cancer in a male transsexual who, similar to our 
case, received antipsychotics and had highly 
elevated PRL levels, and developed triple 
negative Lt. breast cancer [21]. However, the 
patient had received cross-hormonal treatment 
including high dose conjugated estrogens and 
cyproterone acetate for more than 7 years. 
Cyproterone acetate can induce 
hyperprolactinemia, and conjugated estrogens 
independently increase the risk for breast 
cancer, making it harder to speculate on the role 
of the antipsychotic-induced 
hyperprolactinemia in development of breast 
cancer in this case.  
 
One interesting direction that could be 
suggested in learning about the relationship 
between PRL and breast cancer is examining 
the pattern of PRLRs expression on tumor cells 
from patients with highly elevated PRL levels 
and breast cancer. A quantitative and qualitative 
analysis of PRLR isoforms expressed by these 
tumors might provide new information on the 
correlation between PRL and breast cancer. 
Such analysis might also serve to predict tumor 
response to anti-prolactin therapy if these 
tumors prove to be PRL dependent. Although 
the results from studies on the conventional 
anti-prolactin treatment in breast cancer have 
been contradictory and generally disappointing 
[22,23], the newer PRLR antagonists, that 
compete with locally produced (autocrine) PRL 
for receptor binding, might prove to be more 
useful, particularly in such tumors that are PRL 
dependent [16].  
Conclusion 
There is a growing body of evidence on the 
correlation between PRL and breast cancer 
from bench research and epidemiological 
studies. One other potential source of evidence 
comes from reported cases of patients with 
hyperprolactinemia and breast cancer. Our case 
is unique mainly because breast cancer was 
associated with hyperprolactinemia that was 
drug induced rather than due to prolactinoma. 
Quantitative and qualitative analysis of PRLRs 
expressed by tumor cells from such patients 
might provide new insight on the relationship 
between PRL and breast cancer.  
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